These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 35528835)

  • 41. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
    Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
    Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective Effect of
    Biao Y; Chen J; Liu C; Wang R; Han X; Li L; Zhang Y
    Front Pharmacol; 2022; 13():877924. PubMed ID: 35800450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amelioration of free fatty acid-induced fatty liver by quercetin-3-O-β-D-glucuronide through modulation of peroxisome proliferator-activated receptor-alpha/sterol regulatory element-binding protein-1c signaling.
    Wang LL; Zhang ZC; Hassan W; Li Y; Liu J; Shang J
    Hepatol Res; 2016 Feb; 46(2):225-38. PubMed ID: 26190035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease.
    Zhu XY; Xia HG; Wang ZH; Li B; Jiang HY; Li DL; Jin R; Jin Y
    Toxicol Lett; 2020 Feb; 319():85-94. PubMed ID: 31730885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
    J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.
    Zhang M; Yuan Y; Wang Q; Li X; Men J; Lin M
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30291215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease.
    Guo R; Liong EC; So KF; Fung ML; Tipoe GL
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):139-44. PubMed ID: 25865685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
    Choudhary NS; Kumar N; Duseja A
    J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dan-Qi prescription ameliorates insulin resistance through overall corrective regulation of glucose and fat metabolism.
    Xie Z; Loi Truong T; Zhang P; Xu F; Xu X; Li P
    J Ethnopharmacol; 2015 Aug; 172():70-9. PubMed ID: 26087232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roles of PPARs in NAFLD: potential therapeutic targets.
    Tailleux A; Wouters K; Staels B
    Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effects of Chinese herbal medicine Jiangzhi Granule on expressions of liver X receptor α and sterol regulatory element-binding protein-1c in a rat model of non-alcoholic fatty liver disease].
    Yang LL; Wang M; Liu T; Song HY; Li DF; Zheng PY; Liu P; Ji G; Ji G
    Zhong Xi Yi Jie He Xue Bao; 2011 Sep; 9(9):998-1004. PubMed ID: 21906525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.
    Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Fujino T; Yada M; Yada R; Harada N; Enjoji M; Takayanagi R; Nakamuta M
    Int J Mol Med; 2008 Apr; 21(4):507-11. PubMed ID: 18360697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease.
    Nakamuta M; Fujino T; Yada R; Yada M; Yasutake K; Yoshimoto T; Harada N; Higuchi N; Kato M; Kohjima M; Taketomi A; Maehara Y; Nakashima M; Kotoh K; Enjoji M
    Int J Mol Med; 2009 May; 23(5):603-8. PubMed ID: 19360318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
    Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
    Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological properties of tanshinones, the natural products from Salvia miltiorrhiza.
    Wang X; Yang Y; Liu X; Gao X
    Adv Pharmacol; 2020; 87():43-70. PubMed ID: 32089238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
    Musso G; Cassader M; Rosina F; Gambino R
    Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway.
    Chen K; Chen X; Xue H; Zhang P; Fang W; Chen X; Ling W
    Food Funct; 2019 Feb; 10(2):814-823. PubMed ID: 30675881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
    Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
    Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.